US5215989A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
Assignee: Merck and Co Inc
•
Filing: 1991-07-15
•
Granted: 1993-06-01
•
Expires: 2011-07-15
Abstract
Abstract Compounds of structural formula: <IMAGE> wherein Ar is an aromatic ring, B is a cyclic moiety fused to Ar of 5-7 members, X and Y are bridging groups, Q is a nitrogen containing heterocycle, R2 and R3 are H, substituted or unsubtituted C1-3 alkyl, C1-3alkoxy, N(R)2, halogen, CF3 or R5 and R1 is H or an aryl group.
Inventors
- 👤 John J. Baldwin
- 👤 David A. Claremon
- 👤 Jason M. Elliott
- 👤 Gerald S. Ponticello
- 👤 David C. Remy
- 👤 Harold G. Selnick
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 15:34
CPC Classifications
C; C07; C07D; C07D335/00; C07D335/04; C07D335/06; C07D211/00; C07D211/04; C07D211/06; C07D211/08; C07D211/18; C07D211/30; C07D211/32; C07D213/00; C07D213/02; C07D213/04; C07D213/24; C07D213/36; C07D213/38; C07D401/00; C07D401/02; C07D401/06; C07D409/00; C07D409/02; C07D409/12; C07D495/00; C07D495/02; C07D495/04
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
432 words
Compounds of structural formula: ##STR17## or a pharmaceutically acceptable salt thereof, wherein: Ar is an aromatic ring selected from; 1) benzo, 2) thieno, 3) furo, and 4) pyrrolo; B is benzo or other carbocyclic or heterocyclic moiety of 5-7 members fused to the aromatic ring, Ar, with up to 3 variable members independently selected from: 1) S--(O) p , wherein p is 0, 1 or 2, 2) C(R) 2 wherein the R groups are the same or different and represent hydrogen or C 1-5 alkyl, 3) C═O, 4) CHOR, 5) --O-- and 6) NR; Q is piperazine or imidazole; X is --CO--, --CO--NR--(CR 2 ) m --, --SO 2 -- or --(CR 2 ) m -- , wherein m is 0, 1, 2 or 3, or a bond when m is O; Y is --(CR 2 )n--, wherein n is 0, 1, 2 or 3; R 1 is hydrogen if Q is imidazolyl, or if Q is other than imidazolyl, R 1 is pyridyl, benzimidazolyl, pyrimidinyl, phenyl, naphthyl, thienyl, thiazolyl, pyrazinyl, quinolinyl, quinoxalinyl, indolyl, or benzofuranyl, either unsubstituted or substituted with one or more of R 2 , R 3 or R 5 , wherein: R 5 is 1) --N(R)SO 2 C 1-6 alkyl; 2) --N(R)SO 2 (CH 2 ) m CO 2 C 1-6 alkyl; 3) --NO 2 ; 4) --N(R)COC 1-6 alkyl; 5) --N(R)SO 2 --C 6 H 4 --R; 6) --N(R)COC 6 H 4 R; 7) --C 2-6 alkanoyl; 8) CON(R) 2 ; 9) --CN; 10) --CO 2 C 1-6 alkyl; 11) benzoyl, either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, halo, or hydroxy; 12) --NRCOO(C 1-6 alkyl); 13) --NRCOOphenyl either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, hydroxy or halo; 14) --NRCON(R) 2 ; 15) --S(O) p C 1-6 alkyl, wherein p is 0, 1 or 2; 16) --S(O) p phenyl, either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, hydroxy, or halo; 17) phenyl, either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, halo, or hydroxy; 18) imidazolyl; or 19) --SO 2 N(R) 2 ; R 2 and R 3 are independently selected from: 1) hydrogen; 2) C 1-3 alkyl either unsubstituted or substituted with a)--N(R) 2 b)--CON(R) 2 c)--CO(C 1-6 alkyl), d)--O(C 1-6 alkyl), e)--OH, or f)--S(O)p(C 1-6 alkyl); 3) C 1-3 alkoxy; 4) --N(R) 2 ; 5) halo or 6) CF 3 ; 7) R 5 . with the proviso that if R 1 is substituted phenyl, with other than an R 5 substitutent, then one of R 2 or R 3 in the ##STR18##
Claim 2
Dependent Claim
432 words
Compounds of structural formula: ##STR17## or a pharmaceutically acceptable salt thereof, wherein: Ar is an aromatic ring selected from; 1) benzo, 2) thieno, 3) furo, and 4) pyrrolo; B is benzo or other carbocyclic or heterocyclic moiety of 5-7 members fused to the aromatic ring, Ar, with up to 3 variable members independently selected from: 1) S--(O) p , wherein p is 0, 1 or 2, 2) C(R) 2 wherein the R groups are the same or different and represent hydrogen or C 1-5 alkyl, 3) C═O, 4) CHOR, 5) --O-- and 6) NR; Q is piperazine or imidazole; X is --CO--, --CO--NR--(CR 2 ) m --, --SO 2 -- or --(CR 2 ) m -- , wherein m is 0, 1, 2 or 3, or a bond when m is O; Y is --(CR 2 )n--, wherein n is 0, 1, 2 or 3; R 1 is hydrogen if Q is imidazolyl, or if Q is other than imidazolyl, R 1 is pyridyl, benzimidazolyl, pyrimidinyl, phenyl, naphthyl, thienyl, thiazolyl, pyrazinyl, quinolinyl, quinoxalinyl, indolyl, or benzofuranyl, either unsubstituted or substituted with one or more of R 2 , R 3 or R 5 , wherein: R 5 is 1) --N(R)SO 2 C 1-6 alkyl; 2) --N(R)SO 2 (CH 2 ) m CO 2 C 1-6 alkyl; 3) --NO 2 ; 4) --N(R)COC 1-6 alkyl; 5) --N(R)SO 2 --C 6 H 4 --R; 6) --N(R)COC 6 H 4 R; 7) --C 2-6 alkanoyl; 8) CON(R) 2 ; 9) --CN; 10) --CO 2 C 1-6 alkyl; 11) benzoyl, either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, halo, or hydroxy; 12) --NRCOO(C 1-6 alkyl); 13) --NRCOOphenyl either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, hydroxy or halo; 14) --NRCON(R) 2 ; 15) --S(O) p C 1-6 alkyl, wherein p is 0, 1 or 2; 16) --S(O) p phenyl, either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, hydroxy, or halo; 17) phenyl, either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, halo, or hydroxy; 18) imidazolyl; or 19) --SO 2 N(R) 2 ; R 2 and R 3 are independently selected from: 1) hydrogen; 2) C 1-3 alkyl either unsubstituted or substituted with a)--N(R) 2 b)--CON(R) 2 c)--CO(C 1-6 alkyl), d)--O(C 1-6 alkyl), e)--OH, or f)--S(O)p(C 1-6 alkyl); 3) C 1-3 alkoxy; 4) --N(R) 2 ; 5) halo or 6) CF 3 ; 7) R 5 . with the proviso that if R 1 is substituted phenyl, with other than an R 5 substitutent, then one of R 2 or R 3 in the ##STR18##
Claim 3
Dependent Claim
19 words
A compound of claim 1 wherein B has the structure; ##STR19## wherein W is C═O, CH 2 or CHOH.
Claim 4
Dependent Claim
11 words
A compound of claim 2 wherein B has the structure: ##STR20##
Claim 5
Dependent Claim
34 words
A compound of claim 3 wherein R 1 is pyridyl, benzimidazolyl, pyrimidinyl or phenyl, either unsubstituted or substituted with up to three substituents selected from R 2 , R 3 and R 5 .
Claim 6
Dependent Claim
13 words
A compound of claim 4 wherein R 1 is 2-pyridyl, 6-methyl-2-pyridyl or 4-methanesulfonamidophenyl.
Claim 7
Dependent Claim
26 words
A compound selected from 4-{[4-(2-(2-pyridinyl)ethyl)]-1-piperazinyl}thiochromane; 4-{[2-(4-(nitrophenyl)ethyl)]-1-piperazinyl}thiochromane; N-{[4-(4-thiochromanyl)-1-piperazinyl]ethylphenyl}methanesulfonamide; 2-[4-(2-(4-nitrophenyl)ethyl)-piperazin-1-yl]1-tetralone; 2-[4-(2-(2-pyridylethyl))piperazin-1-yl]-1-tetralone; 7-nitro-2-[4-(2-(4-nitrophenyl)ethyl)piperazin-1-yl]-1-tetralone; 2-[4-(2-(4-methanesulfonamidophenyl)ethyl)piperazin-1-yl]-1-tetralone; 7-nitro-2-[4-(2-phenylethyl)piperazin-1-yl]1-tetralone; 7-nitro-2-[4-(2-(2-pyridyl)ethyl)piperazin-1-yl]-1-tetralone; 7-methanesulfonamido-2-[4-(2-phenylethyl)piperazin-1-yl]-1-tetralone; 7-methanesulfonamido-2-[4-(2-(2-pyridyl)ethyl)piperazin-1-yl]-1-tetralone; 6-methanesulfonamido-2-[4-(2-(4-nitrophenyl)ethyl)piperazin-1-yl]-1-tetralone; 1-hydroxy-2-[4-(4-nitrophenethyl)piperazin1-yl]tetralin; 1-hydroxy-2-[4-(2-(2-pyridyl)ethyl)piperazin-1-yl]tetralin; 5,6-dihydro-5-[4'-(2-(2-pyridyl)ethyl)piperazin-1'-yl]methyl-4H-thieno[2,3-b]-thiopyran-4-one; 1-(indole-5-carbonyl)-4-phenethylpiperazine; 1-(indole-5-carbonyl)-4-[2-(4-methanesulfonamidophenyl)ethyl]piperazine; 1-(1H-indole-5-carbonyl)-4-[2-(4-nitrophenyl)ethyl]piperazine; 1-(5,6-dihydro-4H-thieno[2,3-b]thiopyran-4oxo-6-carbonyl)-4-(2-(4-nitrophenyl)ethyl)piperazine; 1-(5,6-dihydro-4H-thieno[2,3-b]thiopyran-4-oxo-6-carbonyl)-4-(2-(2-pyridyl)ethyl)piperazine, and 1-(5,6-dihydro-4H-thieno[2,3-b]thiopyran-4-oxo-6-carbonyl)-4-(4-nitrobenzyl)piperazine.
Claim 8
Dependent Claim
26 words
A compound selected from 4-{[4-(2-(2-pyridinyl)ethyl)]-1-piperazinyl}thiochromane; 4-{[2-(4-(nitrophenyl)ethyl)]-1-piperazinyl}thiochromane; N-{[4-(4-thiochromanyl)-1-piperazinyl]ethylphenyl}methanesulfonamide; 2-[4-(2-(4-nitrophenyl)ethyl)-piperazin-1-yl]1-tetralone; 2-[4-(2-(2-pyridylethyl))piperazin-1-yl]-1-tetralone; 7-nitro-2-[4-(2-(4-nitrophenyl)ethyl)piperazin-1-yl]-1-tetralone; 2-[4-(2-(4-methanesulfonamidophenyl)ethyl)piperazin-1-yl]-1-tetralone; 7-nitro-2-[4-(2-phenylethyl)piperazin-1-yl]1-tetralone; 7-nitro-2-[4-(2-(2-pyridyl)ethyl)piperazin-1-yl]-1-tetralone; 7-methanesulfonamido-2-[4-(2-phenylethyl)piperazin-1-yl]-1-tetralone; 7-methanesulfonamido-2-[4-(2-(2-pyridyl)ethyl)piperazin-1-yl]-1-tetralone; 6-methanesulfonamido-2-[4-(2-(4-nitrophenyl)ethyl)piperazin-1-yl]-1-tetralone; 1-hydroxy-2-[4-(4-nitrophenethyl)piperazin1-yl]tetralin; 1-hydroxy-2-[4-(2-(2-pyridyl)ethyl)piperazin-1-yl]tetralin; 5,6-dihydro-5-[4'-(2-(2-pyridyl)ethyl)piperazin-1'-yl]methyl-4H-thieno[2,3-b]-thiopyran-4-one; 1-(indole-5-carbonyl)-4-phenethylpiperazine; 1-(indole-5-carbonyl)-4-[2-(4-methanesulfonamidophenyl)ethyl]piperazine; 1-(1H-indole-5-carbonyl)-4-[2-(4-nitrophenyl)ethyl]piperazine; 1-(5,6-dihydro-4H-thieno[2,3-b]thiopyran-4oxo-6-carbonyl)-4-(2-(4-nitrophenyl)ethyl)piperazine; 1-(5,6-dihydro-4H-thieno[2,3-b]thiopyran-4-oxo-6-carbonyl)-4-(2-(2-pyridyl)ethyl)piperazine, and 1-(5,6-dihydro-4H-thieno[2,3-b]thiopyran-4-oxo-6-carbonyl)-4-(4-nitrobenzyl)piperazine.
Claim 9
Dependent Claim
17 words
A pharmaceutical formulation comprising a carrier and an effective antiarrhythmic amount of a compound of claim 1.
Claim 10
Dependent Claim
22 words
A pharmaceutical formulation of claim 7 comprising, in addition, a pharmaceutically effective amount of a Class I, II or IV antiarrhythmia agent.
Claim 11
Dependent Claim
31 words
A method for the prevention or treatment of arrhythmia in a member of a mammalian species which comprises the administration of an effective antiarrhythmic amount of a compound of claim 1.
Claim 12
Dependent Claim
24 words
A formulation of claim 7 wherein the amount of the compound is from about 0.0001 to about 20 mg per kg of body weight.
Claim 13
Dependent Claim
24 words
A formulation of claim 7 wherein the amount of the compound is from about 0.001 to about 10 mg per kg of body weight.
References Cited (Backward Citations)
US4806555A
Cited
US4629739A
Cited
US4544654A
Cited
US4783471A
Cited
US4806536A
Cited
EP0235752A2
Cited
EP0242173A1
Cited
US4788196A
Cited
US4797401A
Cited
US4721809A
Cited
US4721809B1
Cited
DE3633977A1
Cited
EP0281254A1
Cited
EP0285284A2
Cited
EP0284384A1
Cited
EP0288277A2
Cited
US4804662A
Cited
EP0296560A2
Cited
EP0300908A1
Cited
EP0307121A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-05-31 | 1996-11-30 | 1997-06-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-05-31 | 2000-11-30 | 2001-06-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-05-31 | 2004-11-30 | 2005-06-01 | $7700.00 | Window Closed / Lapsed |